JP2021503610A - 神経損傷および／または疾患のタンパク質バイオマーカー指標及びその使用の方法 - Google Patents

神経損傷および／または疾患のタンパク質バイオマーカー指標及びその使用の方法 Download PDF

Info

Publication number
JP2021503610A
JP2021503610A JP2020545038A JP2020545038A JP2021503610A JP 2021503610 A JP2021503610 A JP 2021503610A JP 2020545038 A JP2020545038 A JP 2020545038A JP 2020545038 A JP2020545038 A JP 2020545038A JP 2021503610 A JP2021503610 A JP 2021503610A
Authority
JP
Japan
Prior art keywords
protein
biomarkers
proteins
kit
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2020545038A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021503610A5 (https=
Inventor
ミーター ティモシー イー ヴァン
ミーター ティモシー イー ヴァン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Brainbox Solutions Inc
Original Assignee
Brainbox Solutions Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brainbox Solutions Inc filed Critical Brainbox Solutions Inc
Publication of JP2021503610A publication Critical patent/JP2021503610A/ja
Publication of JP2021503610A5 publication Critical patent/JP2021503610A5/ja
Priority to JP2024001282A priority Critical patent/JP2024038290A/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/745—Assays involving non-enzymic blood coagulation factors
    • G01N2333/755—Factors VIII, e.g. factor VIII C [AHF], factor VIII Ag [VWF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/825—Metallothioneins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Genetics & Genomics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
JP2020545038A 2017-11-16 2018-11-15 神経損傷および／または疾患のタンパク質バイオマーカー指標及びその使用の方法 Withdrawn JP2021503610A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024001282A JP2024038290A (ja) 2017-11-16 2024-01-09 神経損傷および／または疾患のタンパク質バイオマーカー指標及びその使用の方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762587272P 2017-11-16 2017-11-16
US62/587,272 2017-11-16
PCT/US2018/061372 WO2019099732A1 (en) 2017-11-16 2018-11-15 Protein biomarker indicators of neurological injury and/or disease and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024001282A Division JP2024038290A (ja) 2017-11-16 2024-01-09 神経損傷および／または疾患のタンパク質バイオマーカー指標及びその使用の方法

Publications (2)

Publication Number Publication Date
JP2021503610A true JP2021503610A (ja) 2021-02-12
JP2021503610A5 JP2021503610A5 (https=) 2022-09-28

Family

ID=66538796

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020545038A Withdrawn JP2021503610A (ja) 2017-11-16 2018-11-15 神経損傷および／または疾患のタンパク質バイオマーカー指標及びその使用の方法
JP2024001282A Pending JP2024038290A (ja) 2017-11-16 2024-01-09 神経損傷および／または疾患のタンパク質バイオマーカー指標及びその使用の方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024001282A Pending JP2024038290A (ja) 2017-11-16 2024-01-09 神経損傷および／または疾患のタンパク質バイオマーカー指標及びその使用の方法

Country Status (4)

Country Link
US (2) US11988676B2 (https=)
EP (1) EP3710836A4 (https=)
JP (2) JP2021503610A (https=)
WO (1) WO2019099732A1 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022176958A1 (ja) * 2021-02-17 2022-08-25 学校法人藤田学園 リンパ球性下垂体前葉炎及びその類縁疾患のマーカー並びにその利用
JP2024000582A (ja) * 2022-06-21 2024-01-09 ａｉｗｅｌｌ株式会社 情報処理システム、特定システムおよびプログラム
WO2025099851A1 (ja) * 2023-11-08 2025-05-15 ａｉｗｅｌｌ株式会社 情報処理システム、特定システムおよびプログラム

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3688020A4 (en) 2017-09-25 2021-07-14 University of Florida Research Foundation, Incorporated IMMUNOASSAYS FOR DETECTION OF RAN PROTEINS
EP3779448A1 (en) * 2019-08-12 2021-02-17 Baden-Württemberg Stiftung gGmbH Novel diagnostic marker for creutzfeldt-jakob disease and alzheimer's disease
US20220326258A1 (en) * 2019-09-13 2022-10-13 Northwestern University Biomarkers for amyotrophic lateral sclerosis (als) and motor neuron diseases
WO2021055880A1 (en) * 2019-09-20 2021-03-25 University Of Florida Researchfoundation, Incorporated Detection of antibodies against ran proteins from serum and tissue lysates
EP4111197A1 (en) * 2020-02-25 2023-01-04 Markus Otto Diagnosing a disease associated with synaptic degeneration using an elisa for determining a beta-synuclein concentration in csf
WO2023092157A1 (en) * 2021-11-22 2023-05-25 Brainbox Solutions, Inc. Biomarker testing for chronic persistent injury following brain trauma
WO2024050133A1 (en) * 2022-09-01 2024-03-07 GATC Health Corp Digital twin for diagnostic and therapeutic use

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005522669A (ja) * 2001-08-20 2005-07-28 バイオサイト インコーポレイテッド 卒中および脳損傷の診断マーカーおよびその使用方法
US20120015904A1 (en) * 2010-07-14 2012-01-19 Regents Of The University Of California Biomarkers for diagnosis of transient ischemic attacks
WO2012068642A1 (en) * 2010-11-26 2012-05-31 Immunexpress Pty Ltd Diagnostic and/or screening agents and uses therefor
US20140371098A1 (en) * 2011-12-22 2014-12-18 Protagen Ag Marker sequences for breast cancer and the use thereof
WO2016179426A1 (en) * 2015-05-05 2016-11-10 The Regents Of The University Of California Astrocyte traumatome and neurotrauma biomarkers
US20170145506A1 (en) * 2015-11-24 2017-05-25 University Of Rochester Signature of Longitudinal Gene Expression Changes to Diagnose Brain Injury

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10809271B2 (en) * 2015-03-27 2020-10-20 The Translational Genomics Research Institute Biomarkers and methods of diagnosing and prognosing mild traumatic brain injuries
JP2018524575A (ja) 2015-06-18 2018-08-30 シーダーズ−サイナイ メディカル センター 疾患の診断におけるシトルリン化の役割

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005522669A (ja) * 2001-08-20 2005-07-28 バイオサイト インコーポレイテッド 卒中および脳損傷の診断マーカーおよびその使用方法
US20120015904A1 (en) * 2010-07-14 2012-01-19 Regents Of The University Of California Biomarkers for diagnosis of transient ischemic attacks
WO2012068642A1 (en) * 2010-11-26 2012-05-31 Immunexpress Pty Ltd Diagnostic and/or screening agents and uses therefor
US20140371098A1 (en) * 2011-12-22 2014-12-18 Protagen Ag Marker sequences for breast cancer and the use thereof
WO2016179426A1 (en) * 2015-05-05 2016-11-10 The Regents Of The University Of California Astrocyte traumatome and neurotrauma biomarkers
US20170145506A1 (en) * 2015-11-24 2017-05-25 University Of Rochester Signature of Longitudinal Gene Expression Changes to Diagnose Brain Injury

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022176958A1 (ja) * 2021-02-17 2022-08-25 学校法人藤田学園 リンパ球性下垂体前葉炎及びその類縁疾患のマーカー並びにその利用
JPWO2022176958A1 (https=) * 2021-02-17 2022-08-25
JP2024000582A (ja) * 2022-06-21 2024-01-09 ａｉｗｅｌｌ株式会社 情報処理システム、特定システムおよびプログラム
JP7670286B2 (ja) 2022-06-21 2025-04-30 ａｉｗｅｌｌ株式会社 情報処理システム、特定システムおよびプログラム
JP2025115992A (ja) * 2022-06-21 2025-08-07 ａｉｗｅｌｌ株式会社 情報処理システムおよびプログラム
WO2025099851A1 (ja) * 2023-11-08 2025-05-15 ａｉｗｅｌｌ株式会社 情報処理システム、特定システムおよびプログラム

Also Published As

Publication number Publication date
JP2024038290A (ja) 2024-03-19
EP3710836A4 (en) 2021-10-27
US20200355701A1 (en) 2020-11-12
US11988676B2 (en) 2024-05-21
WO2019099732A1 (en) 2019-05-23
US20250044303A1 (en) 2025-02-06
EP3710836A1 (en) 2020-09-23

Similar Documents

Publication Publication Date Title
US12339288B2 (en) Multi-protein biomarker assay for brain injury detection and outcome
US20250044303A1 (en) Protein biomarker indicators of neurological injury and/or disease and methods of use thereof
US12265091B2 (en) Circulating biomarker levels for diagnosis and risk-stratification of traumatic brain injury
US12422433B2 (en) Blood biomarker that predicts persistent cognitive dysfunction after concussion
US12461112B2 (en) Biomarker levels and neuroimaging for detecting, monitoring and treating brain injury or trauma
US20230238143A1 (en) Multimodality systems and methods for detection, prognosis, and monitoring of neurological injury and disease
WO2014207888A1 (ja) 認知機能障害疾患のバイオマーカー及び当該バイオマーカーを用いる認知機能障害疾患の検出方法
US20140147874A1 (en) Biomarkers of cardiac ischemia
US20250155455A1 (en) Protein biomarker indicators of neurological injury and/or disease and methods of use thereof
US20250035650A1 (en) Biomarker testing for chronic persistent injury following brain trauma
WO2019012667A1 (ja) 認知機能障害疾患のバイオマーカー及び該バイオマーカーを用いる認知機能障害疾患の検出方法
WO2025179300A1 (en) Biomarkers, compositions, kits, and methods distinguishing acute geriatric tbi from pre-existing dementia or cognitive impairment
EP2644704A1 (de) Markersequenzen für Rheumatoide Arthritis

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201124

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211112

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20211112

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20220826

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20220826

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220902

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20221019

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221202

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230202

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230602

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230907

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240109

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20240209

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20240531

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20250827